journal
MENU ▼
Read by QxMD icon Read
search

Therapeutic Advances in Cardiovascular Disease

journal
https://www.readbyqxmd.com/read/29996720/results-of-5-year-follow-up-study-in-patients-with-peripheral-artery-disease-treated-with-pl-vegf165-for-intermittent-claudication
#1
Roman Deev, Igor Plaksa, Ilia Bozo, Nina Mzhavanadze, Igor Suchkov, Yuriy Chervyakov, Ilia Staroverov, Roman Kalinin, Artur Isaev
BACKGROUND: The effective treatment of chronic lower limb ischemia is one of the most challenging issues confronting vascular surgeons. Current pharmacological therapies play an auxiliary role and cannot prevent disease progression, and new treatment methods are needed. In 2011, a plasmid VEGF65-gene therapy drug was approved in Russia for the treatment of chronic lower limb ischemia ( ClinicalTrials.gov identifier: NCT03068585). The objective of this follow-up study was to evaluate the long-term safety and efficacy of gene therapy in patients with limb ischemia of atherosclerotic genesis...
July 1, 2018: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/29996707/retraction-notice
#2
(no author information available yet)
No abstract text is available yet for this article.
July 1, 2018: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/29921166/sacubitril-valsartan-in-cardiovascular-disease-evidence-to-date-and-place-in-therapy
#3
Srikanth Yandrapalli, Mohammed Hasan Khan, Yogita Rochlani, Wilbert S Aronow
Cardiovascular (CV) disease is a major cause of morbidity and mortality in the developing and the developed world. Mortality from CV disease had plateaued in the recent years raising concerning alarms about the sustained efficacy of available preventive and treatment options. Heart failure (HF) is among the major contributors to the CV-related health care burden, a persisting concern despite the use of clinically proven guideline-directed therapies. A requirement for more efficient medical therapies coupled with recent advances in bio-innovation led to the creation of sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), which demonstrated substantial CV benefit when compared with the standard of care, enalapril, in patients with HF and reduced ejection fraction...
June 1, 2018: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/29914293/evaluation-of-the-impact-of-body-mass-index-on-warfarin-requirements-in-hospitalized-patients
#4
Katie B Tellor, Steffany N Nguyen, Amanda C Bultas, Anastasia L Armbruster, Nicholas A Greenwald, Abigail M Yancey
BACKGROUND: Despite well established empiric dose adjustments for drug and disease-state interactions, the impact of body mass index (BM) on warfarin remains unclear. The objective of this study is to evaluate warfarin requirements in hospitalized patients, stratified by BMI. METHODS: This retrospective review included two cohorts of patients: cohort A (patients admitted with a therapeutic international normalized ratio (INR)) and cohort B (newly initiated on warfarin during hospitalization)...
June 1, 2018: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/29860927/conference-report-the-67th-american-college-of-cardiology-conference
#5
Elena Conroy
No abstract text is available yet for this article.
August 2018: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/29848191/cystatin-c-and-galectin-3-as-therapeutic-targets-in-heart-failure
#6
Christos Zivlas, Filippos Triposkiadis, Stelios Psarras, Gregory Giamouzis, Ioannis Skoularigis, Stavros Chryssanthopoulos, Alkistis Kapelouzou, Steve Ramcharitar, Edward Barnes, Evangelos Papasteriadis, Dennis Cokkinos
No abstract text is available yet for this article.
August 2018: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/29792380/alirocumab-as-add-on-therapy-to-statins-current-evidence-and-clinical-potential
#7
Johann Auer, Robert Berent
Atherosclerotic cardiovascular diseases (ASCVDs) are associated with a substantial mortality, physical morbidity, and mental disability. Elevated plasma low-density lipoprotein cholesterol (LDL-C) levels play a major role in the pathophysiology of ASCVDs. Statins have been shown to reduce ASCVD risk and associated events and are recommended as first-line therapy for treatment of hypercholesterolemia by current international guidelines. The key issue is to attain guideline-recommended LDL-C levels (below 70 mg/dl) for patients at very high cardiovascular risk...
July 2018: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/29764302/anandamide-and-endocannabinoid-system-an-attractive-therapeutic-approach-for-cardiovascular-disease
#8
Virna Margarita Martín Giménez, Sandra Edith Noriega, Diego Enrique Kassuha, Lucía Beatriz Fuentes, Walter Manucha
Cardiovascular disease is currently not adequately managed and has become one of the main causes of morbidity and mortality worldwide. Current therapies are inadequate in terms of preventing its progression. There are several limitations, such as poor oral bioavailability, side effects, low adherence to treatment, and high dosage frequency of formulations due to the short half-life of the active ingredients used, among others. This review aims to highlight the most relevant aspects of the relationship between the cardiovascular system and the endocannabinoid system, with special attention to the possible translational effect of the use of anandamide in cardiovascular health...
July 2018: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/29589515/rheolytic-effects-of-left-main-mid-shaft-distal-stenting-a-computational-flow-dynamic-analysis
#9
Gianluca Rigatelli, Marco Zuin, Fabio Dell'Avvocata, Thach Nguyen
Background The aim of this study was to evaluate the rheolytic effects of stenting a mid-shaft/distal left main coronary artery (LMCA) lesion with and without ostial coverage. Stenting of the LMCA has emerged as a valid alternative in place of traditional coronary bypass graft surgery. However, in case of mid-shaft/distal lesion, there is no consensus regarding the extension of the strut coverage up to the ostium or to stent only the culprit lesion. Methods We reconstructed a left main-left descending coronary artery (LM-LCA)-left circumflex (LCX) bifurcation after analysing 100 consecutive patients (mean age 71...
June 2018: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/29546816/polypill-an-affordable-strategy-for-cardiovascular-disease-prevention-in-low-medium-income-countries
#10
Patricio López-Jaramillo, Silvia González-Gómez, Diego Zarate-Bernal, Andrés Serrano, Leonor Atuesta, Christian Clausen, Claudia Castro-Valencia, Paul Camacho-Lopez, Johanna Otero
The simplification of fixed dose medications by using a single 'polypill' is an attractive strategy to improve adherence to medications which has shown benefit to cardiovascular risk factor control and cardiovascular disease prevention or delay in the progression of these diseases. We review the evidence obtained from a series of clinical trials demonstrating an improvement in adherence to the polypill compared to the use of each compound separately, and found similar or better control of the classical cardiovascular risk factors and a similar safety profile...
June 2018: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/29421960/letter-to-the-editor-regarding-the-article-left-atrial-volume-index-in-patients-with-heart-failure-and-severely-impaired-left-ventricular-systolic-function-the-role-of-established-echocardiographic-parameters-circulating-cystatin-c-and-galectin-3-by-zivlas
#11
https://www.readbyqxmd.com/read/29457533/pyogenic-infection-of-the-hip-joint-as-a-complication-of-a-femoral-artery-vascular-access-for-percutaneous-coronary-intervention
#12
Jaroslaw Ucieklak, Robert Michał Proczka
A rare case of clinical complication following a percutaneous coronary intervention is presented. A femoral vascular access was chosen to treat a coronary lesion with a stent implantation. This femoral vascular access, however, resulted in a pyogenic infection of the ipsilateral hip joint that was not properly diagnosed for an extended post-interventional period. The hip joint completely deteriorated before its underlying cause was identified. This case report illustrates the importance of recognizing potential endovascular complications independently of their frequency...
May 2018: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/29431578/patency-of-the-arterial-pedal-plantar-arch-in-patients-with-chronic-kidney-disease-or-diabetes-mellitus
#13
Axel Haine, Alan G Haynes, Andreas Limacher, Tim Sebastian, Wuttichai Saengprakai, Torsten Fuss, Iris Baumgartner
BACKGROUND: Patency of the pedal-plantar arch limits risk of amputation in peripheral artery disease (PAD). We examined patients without chronic kidney disease (CKD)/diabetes mellits (DM) [PAD-control], those with DM without CKD, and those with CKD without DM. METHOD: Uni- and multivariate logistic regression was used to assess association of CKD with loss of patency of the pedal-plantar arch and presence of tibial or peroneal vessel occlusion. Multivariate models adjusted for age, sex, hypertension, hyperlipidemia and smoking...
May 2018: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/29421959/accelerated-ambulation-after-vascular-access-closure-device
#14
Daniel Brancheau, Sinan Sarsam, Mahmoud Assaad, Marcel Zughaib
BACKGROUND: Patients who are candidates to receive an Angioseal® (St. Jude Medical) device for arteriotomy closure are allowed to ambulate 20 min after the deployment of the device. More frequently, however, patients are kept on bed rest for several hours following Angioseal® deployment. The purpose of this study was to prospectively assess patients when ambulating 20 min after Angioseal® deployment instead of prolonged best rest of 2-3 h. METHODS: Patients undergoing angiography from the common femoral artery approach were included in the study if they received a 6 Fr Angioseal® closure device...
May 2018: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/29528779/differential-mrna-expression-of-inflammasome-genes-nlrp1-and-nlrp3-in-abdominal-aneurysmal-and-occlusive-aortic-disease
#15
Carmen Gonzalez-Hidalgo, Joaquin De Haro, Silvia Bleda, Cristina Cañibano, Ignacio Michel, Francisco Acin
NLRP1 and NLRP3 inflammasomes might differentially mediate the chronic inflammatory response in abdominal aortic aneurysm (AAA) and aortic occlusive disease (AOD). We measure differential relative gene expression of NLRP1 and NLRP3 inflammasomes in aortic tissues from 30 patients undergoing AAA open repair compared to aortic biopsies from 30 patients undergoing surgery to treat AOD. Aortic wall samples from autopsy without aortic disease were used as controls. NLRP3 was overexpressed in patients with AAA and AOD (RQ 1...
April 2018: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/29528778/physician-decision-making-in-anticoagulating-atrial-fibrillation-a-prospective-survey-of-a-physician-notification-system-for-atrial-fibrillation-detected-on-cardiac-implantable-electronic-devices-of-patients-at-increased-risk-of-stroke
#16
Justin M Cloutier, Clarence Khoo, Brett Hiebert, Anthony Wassef, Colette M Seifer
OBJECTIVES: The objectives of this study were to evaluate the effectiveness of a physician notification system for atrial fibrillation (AF) detected on cardiac devices, and to assess predictors of anticoagulation in patients with device-detected AF. METHODS: In 2013, a physician notification system for AF detected on a patient's CIED [including pacemakers, implantable cardioverter defibrillators (ICD) or cardiac resynchronization therapy (CRT) devices] was implemented, with a recommendation to consider oral anticoagulation in high-risk patients...
April 2018: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/29529959/impact-of-prolonged-utilization-of-neprilysin-inhibition-on-the-cognitive-function-of-heart-failure-patients
#17
Niel N Shah, Muhammad U Dogar, Parin N Shah, Sameera Ishtiaq, Shawn Mathew, Pratik Shah, Alia Ishtiaq, Timothy J Vittorio
No abstract text is available yet for this article.
March 1, 2018: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/29316855/the-role-of-noninvasive-cardiovascular-testing-applied-clinical-nutrition-and-nutritional-supplements-in-the-prevention-and-treatment-of-coronary-heart-disease
#18
Mark Houston
Numerous clinical trials suggest that we have reached a limit in our ability to decrease the incidence of coronary heart disease (CHD) and cardiovascular disease (CVD) utilizing the traditional diagnostic evaluation, prevention and treatment strategies for the top five cardiovascular risk factors of hypertension, diabetes mellitus, dyslipidemia, obesity and smoking. About 80% of heart disease (heart attacks, angina, coronary heart disease and congestive heart failure) can be prevented by optimal nutrition, optimal exercise, optimal weight and body composition, mild alcohol intake and avoiding smoking...
March 2018: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/29307269/same-day-dual-radial-artery-puncture-examination-in-patients-requiring-percutaneous-coronary-intervention-and-the-incidence-of-radial-artery-occlusion
#19
Daniel Brancheau, Sachin Kumar Amruthlal Jain, Patrick B Alexander
BACKGROUND: We sought to investigate the rate of radial artery occlusion (RAO) after same-day dual radial artery puncture. The trans-radial arterial approach (TRA) for diagnostic and interventional procedures has risen significantly in the United States. Although becoming more commonly performed, TRA is not without risk, and a potential complication is RAO. The rate of RAO after same-day dual artery puncture is unknown. METHODS: A retrospective analysis of 27 patients who underwent same-day dual radial artery puncture for percutaneous coronary intervention (PCI) at our institution (Providence Heart Institute in Southfield, MI, USA) from November 2011 to December 2013 were included after initially presenting for cardiac catheterization at a non-PCI-capable facility...
March 2018: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/29271292/chronic-limb-threatening-ischemia-could-benefit-from-growth-hormone-therapy-for-wound-healing-and-limb-salvage
#20
Diego Caicedo, Pablo Devesa, Víctor M Arce, Julia Requena, Jesús Devesa
Revascularization for chronic limb-threatening ischemia (CLTI) is necessary to alleviate symptoms and wound healing. When it fails or is not possible, there are few alternatives to avoid limb amputation in these patients. Although experimental studies with stem cells and growth factors have shown promise, clinical trials have demonstrated inconsistent results because CLTI patients generally need arteriogenesis rather than angiogenesis. Moreover, in addition to the perfusion of the limb, there is the need to improve the neuropathic response for wound healing, especially in diabetic patients...
February 2018: Therapeutic Advances in Cardiovascular Disease
journal
journal
41744
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"